Effects of FX06 In vitro on platelet, coagulation, and fibrinolytic biomarkers in volunteers and patientswith documented coronary artery disease

American Journal of Therapeutics

Volumn 21, Issue 2, 2014, Pages 91-98

  Hallén, Jonas ^a   Atar, Dan ^a   Serebruany, Victor ^b  

^a UNIVERSITY OF OSLO   (Norway)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Coagulation; Fibrin derived peptide; Fibrinolysis; FX06; Platelets; Reperfusion injury; ST elevation myocardial infarction

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ALPHA 2 ANTIPLASMIN; ANTIDEPRESSANT AGENT; ANTITHROMBIN III; BATROXOBIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD31 ANTIGEN; COLLAGEN; D DIMER; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRIN DERIVATIVE; FIBRINOGEN; FIBRINOGEN DEGRADATION PRODUCT; FX 06; GLYCOPROTEIN IB; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLASMINOGEN; PROTEIN C; PROTEIN S; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; VON WILLEBRAND FACTOR;

ADULT; AFRICAN AMERICAN; AGE; ANTIGEN EXPRESSION; ARTICLE; ASIAN; BLOOD CLOTTING; BLOOD CLOTTING TIME; BLOOD SAMPLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; EUROPEAN AMERICAN; EVALUATION STUDY; FAMILY HISTORY; FEMALE; FIBRINOLYSIS; FLOW CYTOMETRY; GENDER; HEART FAILURE; HEART SURGERY; HEMOSTASIS; HISPANIC; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; HYPERTENSION; IN VITRO STUDY; MALE; MEDICAL HISTORY; MIDDLE AGED; NORMAL HUMAN; OBESITY; PARTIAL THROMBOPLASTIN TIME; PERIPHERAL VASCULAR DISEASE; PREMEDICATION; PRIORITY JOURNAL; PROTHROMBIN TIME; RACE; RISK FACTOR; SEDENTARY LIFESTYLE; SMOKING; THROMBIN TIME; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; UPREGULATION; VASCULAR DISEASE;

ADULT; ASPIRIN; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOLYSIS; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE; YOUNG ADULT;

EID: 84896339377     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e3181b0a6ff     Document Type: Article

References (18)

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3:e442.
2. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest. 1985;76:1713-1719.
3. Hausenloy DJ, Yellon DM. Time to take myocardial reperfusion injury seriously. N Engl J Med. 2008;359:518-520.
4. Dirksen MT, Laarman GJ, Simoons ML, et al. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies. Cardiovasc Res. 2007;74:343-355.
5. Zacharowski K, Zacharowski P, Reingruber S, et al. Fibrin(ogen) and its fragments in the pathophysiology and treatment of myocardial infarction. J Mol Med. 2006; 84:469-477.
6. Atar D, Petzelbauer P, Schwitter J, et al. Effect of intravenous FX06 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction results of the F.I.R.E. (Efficacy of FX06 in the Prevention of Myocardial Reperfusion Injury) trial. J Am Coll Cardiol. 2009;53:720-729.
7. Gawaz M. Role of platelets in coronary thrombosis and reperfusion of ischemic myocardium. Cardiovasc Res. 2004;61:498-511.
8. Tennant R, Wiggers CJ. The effect of coronary occlusion on myocardial contraction. Am J Physiol. 1935;112: 351-361.
9. Jennings RB, Sommers HM, Smyth GA, et al. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol. 1960;70:68-78.
10. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res. 2004;61:481-497.
11. Bazzoni G, Dejana E, Del MA. Platelet-neutrophil interactions. Possible relevance in the pathogenesis of thrombosis and inflammation. Haematologica. 1991;76:491-499.
12. Petzelbauer P, Zacharowski PA, Miyazaki Y, et al. The fibrin-derived peptide Bbeta15-42 protects the myocardium against ischemia-reperfusion injury. Nat Med. 2005; 11:298-304.
13. Hamaguchi M, Bunce LA, Sporn LA, et al. Spreading of platelets on fibrin is mediated by the amino terminus of the beta chain including peptide beta 15-42. Blood. 1993; 81:2348-2356.
14. Xu Y, Huo Y, Toufektsian MC, et al. Activated platelets contribute importantly to myocardial reperfusion injury. Am J Physiol Heart Circ Physiol. 2006;290:H692-H699.
15. Singbartl K, Forlow SB, Ley K. Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J. 2001;15:2337-2344.
16. Mazzocchi F. Complexity in biology. Exceeding the limits of reductionism and determinism using complexity theory. EMBO Rep. 2008;9:10-14.
17. Van Regenmortel MH. Reductionism and complexity in molecular biology. Scientists now have the tools to unravel biological and overcome the limitations of reductionism. EMBO Rep. 2004;5:1016-1020.
18. Kellenberger E. The evolution of molecular biology. EMBO Rep. 2004;5:546-549.